Akram M
Department of Eastern Medicine and Surgery, Faculty of Medical and Health Sciences, The University of Poonch, Azad Jammu and Kashmir, Pakistan.
J Cancer Educ. 2013 Sep;28(3):454-7. doi: 10.1007/s13187-013-0486-9.
Glycolysis is a universal pathway in the living cells. The complete pathway of glycolysis was elucidated in 1940. This pathway is often referred to as Embden-Meyerhof pathway in honor of the two biochemists that made a major contribution to the knowledge of glycolysis. The objective of the study was to review the published literature on glycolysis and relation to cancer. The material for this review was taken mostly from up-to-date biochemistry textbooks and electronic journals. To collect publications, PubMed and the Cochrane database of systematic reviews were used. Some other relevant references were collected from personal database of papers on glycolysis and cancer. Several glycolytic inhibitors are currently in preclinical and clinical development. Inhibition of glycolysis in cancer cells is a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. This article is an important topic to be considered by cancer researchers and those who treat cancers.
糖酵解是活细胞中的一条普遍途径。糖酵解的完整途径于1940年阐明。为纪念两位对糖酵解知识做出重大贡献的生物化学家,该途径常被称为Embden-Meyerhof途径。本研究的目的是回顾已发表的关于糖酵解及其与癌症关系的文献。本综述的资料主要取自最新的生物化学教科书和电子期刊。为收集出版物,使用了PubMed和Cochrane系统评价数据库。其他一些相关参考文献则从关于糖酵解和癌症的个人论文数据库中收集。目前有几种糖酵解抑制剂正处于临床前和临床开发阶段。抑制癌细胞中的糖酵解是克服与线粒体呼吸缺陷和缺氧相关的耐药性的一种新策略。本文是癌症研究人员和癌症治疗人员需要考虑的一个重要课题。